ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for BCRX

Stock NameBioCryst Pharmaceuticals Inc
TickerBCRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS09058V1035
LEI549300Z0INP1Z5NP6J59

Show aggregate BCRX holdings

News associated with BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price […] - 2025-09-05 04:29:03
Headlands Technologies LLC Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,219 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of […] - 2025-08-14 04:45:23
New Age Alpha Advisors LLC Takes $62,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
New Age Alpha Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,235 shares of the biotechnology company’s stock, valued at approximately $62,000. A number of other institutional […] - 2025-08-12 05:00:48
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year […] - 2025-08-11 02:28:49
XTX Topco Ltd Acquires 66,320 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
XTX Topco Ltd increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 314.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,389 shares of the biotechnology company’s stock after purchasing an additional 66,320 shares during the […] - 2025-08-06 05:57:13
Mackenzie Financial Corp Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Mackenzie Financial Corp grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 37.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,258 shares of the biotechnology company’s stock after purchasing an additional 31,596 shares during the period. […] - 2025-08-06 05:18:53
Universal Beteiligungs und Servicegesellschaft mbH Makes New $125,000 Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,704 shares of the biotechnology company’s stock, valued at approximately $125,000. Other hedge funds have also modified their […] - 2025-08-06 04:28:49
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Strong Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares gapped up before the market opened on Monday following a stronger than expected earnings report. The stock had previously closed at $7.95, but opened at $9.14. BioCryst Pharmaceuticals shares last traded at $8.32, with a volume of 2,333,940 shares traded. The biotechnology company reported $0.15 earnings […] - 2025-08-06 02:13:11
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Cerity Partners LLC
Cerity Partners LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 203.6% in the 1st quarter, Holdings Channel reports. The firm owned 36,410 shares of the biotechnology company’s stock after purchasing an additional 24,418 shares during the period. Cerity Partners LLC’s holdings in BioCryst Pharmaceuticals were worth $273,000 at the end […] - 2025-07-28 04:46:48
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday. A number of other research firms have also recently commented on BCRX. Needham & Company LLC restated a “buy” rating […] - 2025-07-28 02:18:50
Y Intercept Hong Kong Ltd Buys 73,242 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Y Intercept Hong Kong Ltd grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 106.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 141,865 shares of the biotechnology company’s stock after purchasing an additional 73,242 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth […] - 2025-07-25 06:52:53
Bank of America Raises BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price raised by equities research analysts at Bank of America from $13.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s target price indicates a potential upside of […] - 2025-07-03 04:38:51
Wedbush Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price target raised by research analysts at Wedbush from $16.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would indicate a potential upside of 100.00% from the company’s current price. […] - 2025-07-02 02:32:50
BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Outperform” Rating from Royal Bank Of Canada
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Royal Bank Of Canada in a report released on Monday,Benzinga reports. They currently have a $13.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 44.44% from the […] - 2025-07-02 02:32:47
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 5.2% during the first quarter, HoldingsChannel reports. The fund owned 43,496 shares of the biotechnology company’s stock after acquiring an additional 2,146 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $326,000 […] - 2025-06-26 04:58:58
Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $16.56
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year […] - 2025-06-25 02:44:54
Peek Under The Hood: FHLC Has 21% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-20 08:15:40
Millennium Management LLC Sells 634,095 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Millennium Management LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 44.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,105 shares of the biotechnology company’s stock after selling 634,095 shares during the quarter. Millennium Management LLC’s holdings […] - 2025-05-28 04:56:50
ProShare Advisors LLC Has $511,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
ProShare Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,004 shares of the biotechnology company’s stock after purchasing an additional 16,732 shares during the period. ProShare […] - 2025-05-27 05:36:51
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plc
Man Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company’s stock after purchasing an additional 28,481 shares during the period. Man Group […] - 2025-05-26 05:01:05
Wall Street Zen Upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to “Strong-Buy”
Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a buy rating to a strong-buy rating in a research note published on Thursday. BCRX has been the subject of several other research reports. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the […] - 2025-05-23 04:32:52
Lazard Asset Management LLC Buys 65,420 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Lazard Asset Management LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 68.1% during the fourth quarter, Holdings Channel reports. The fund owned 161,516 shares of the biotechnology company’s stock after acquiring an additional 65,420 shares during the quarter. Lazard Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $1,214,000 as […] - 2025-05-20 06:00:50
The Manufacturers Life Insurance Company Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
The Manufacturers Life Insurance Company decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 65.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 103,531 shares of the biotechnology company’s stock after selling 195,621 shares during the period. The Manufacturers Life Insurance Company’s holdings in […] - 2025-05-15 04:45:06
10,670 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Raymond James Financial Inc.
Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,670 shares of the biotechnology company’s stock, valued at approximately $80,000. Several other institutional […] - 2025-05-14 04:26:53
Mariner LLC Grows Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Mariner LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,258 shares of the biotechnology company’s stock after purchasing an additional 3,224 shares during the quarter. […] - 2025-05-09 05:08:42
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC
BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […] - 2025-05-09 04:26:42
Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology company’s stock, valued at approximately $748,000. A number of other institutional […] - 2025-05-08 06:44:51
JPMorgan Chase & Co. Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $10.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.97% […] - 2025-05-08 05:04:48
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Earnings Beat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $8.93, but opened at $9.80. BioCryst Pharmaceuticals shares last traded at $10.03, with a volume of 5,915,215 shares changing hands. The biotechnology […] - 2025-05-07 02:20:57
Investors Buy Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 2,675 call options on the company. This represents an increase of approximately 174% compared to the average daily volume of 975 call options. BioCryst Pharmaceuticals Price Performance Shares of BCRX stock opened at […] - 2025-05-07 02:20:55

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) BCRX holdings

DateNumber of BCRX Shares HeldBase Market Value of BCRX SharesLocal Market Value of BCRX SharesChange in BCRX Shares HeldChange in BCRX Base ValueCurrent Price per BCRX Share HeldPrevious Price per BCRX Share Held
2025-12-03 (Wednesday)145,965USD 1,145,825USD 1,145,825
2025-12-02 (Tuesday)145,965BCRX holding increased by 5235USD 1,045,109BCRX holding increased by 41704USD 1,045,1095,235USD 41,704 USD 7.16 USD 7.13
2025-12-01 (Monday)140,730USD 1,003,405BCRX holding decreased by -7036USD 1,003,4050USD -7,036 USD 7.13 USD 7.18
2025-11-28 (Friday)140,730BCRX holding increased by 349USD 1,010,441BCRX holding increased by 13736USD 1,010,441349USD 13,736 USD 7.18 USD 7.1
2025-11-27 (Thursday)140,381USD 996,705USD 996,7050USD 0 USD 7.1 USD 7.1
2025-11-26 (Wednesday)140,381BCRX holding increased by 1047USD 996,705BCRX holding increased by 42267USD 996,7051,047USD 42,267 USD 7.1 USD 6.85
2025-11-25 (Tuesday)139,334BCRX holding increased by 1745USD 954,438BCRX holding increased by 14705USD 954,4381,745USD 14,705 USD 6.85 USD 6.83
2025-11-24 (Monday)137,589BCRX holding increased by 350USD 939,733BCRX holding decreased by -16823USD 939,733350USD -16,823 USD 6.83 USD 6.97
2025-11-21 (Friday)137,239USD 956,556BCRX holding decreased by -8234USD 956,5560USD -8,234 USD 6.97 USD 7.03
2025-11-20 (Thursday)137,239BCRX holding decreased by -1392USD 964,790BCRX holding increased by 4077USD 964,790-1,392USD 4,077 USD 7.03 USD 6.93
2025-11-19 (Wednesday)138,631BCRX holding increased by 348USD 960,713BCRX holding decreased by -7268USD 960,713348USD -7,268 USD 6.93 USD 7
2025-11-18 (Tuesday)138,283BCRX holding increased by 2088USD 967,981BCRX holding increased by 10530USD 967,9812,088USD 10,530 USD 7 USD 7.03
2025-11-17 (Monday)136,195BCRX holding increased by 696USD 957,451BCRX holding decreased by -1882USD 957,451696USD -1,882 USD 7.03 USD 7.08
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of BCRX by Blackrock for IE00BYXG2H39

Show aggregate share trades of BCRX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-02BUY5,2357.3007.115 7.133USD 37,344 8.25
2025-11-28BUY3497.2257.060 7.077USD 2,470 8.26
2025-11-26BUY1,0477.1406.810 6.843USD 7,165 8.27
2025-11-26BUY1,0477.1406.810 6.843USD 7,165 8.27
2025-11-25BUY1,7457.0106.705 6.735USD 11,753 8.28
2025-11-24BUY3507.0506.710 6.744USD 2,360 8.28
2025-11-20SELL-1,3927.0906.895 6.914USD -9,625 8.30 Profit of 1,924 on sale
2025-11-19BUY3487.0716.735 6.769USD 2,355 8.30
2025-11-18BUY2,0887.1256.970 6.985USD 14,586 8.31
2025-11-17BUY6967.2057.010 7.030USD 4,893 8.32
2025-11-14BUY3487.1856.860 6.893USD 2,399 8.32
2025-11-12BUY3487.3157.140 7.158USD 2,491 8.34
2025-11-10BUY3467.2707.080 7.099USD 2,456 8.35
2025-11-06BUY3467.1506.870 6.898USD 2,387 8.36
2025-11-04BUY3486.8956.510 6.549USD 2,279 8.37
2025-10-30BUY1,7407.4307.215 7.237USD 12,592 8.39
2025-10-29BUY6967.3107.370 7.364USD 5,125 8.40
2025-10-22SELL-1,3887.0807.160 7.152USD -9,927 8.43 Profit of 1,776 on sale
2025-10-20BUY6946.9306.930 6.930USD 4,809 8.45
2025-10-17BUY1,7336.6306.680 6.675USD 11,568 8.46
2025-10-15BUY2,7606.8106.880 6.873USD 18,969 8.47
2025-10-03BUY2,4367.1507.470 7.438USD 18,119 8.49
2025-10-02BUY3487.3307.420 7.411USD 2,579 8.49
2025-09-30BUY6967.5907.620 7.617USD 5,301 8.50
2025-09-26BUY6967.6307.730 7.720USD 5,373 8.51
2025-09-25BUY6967.6507.890 7.866USD 5,475 8.52
2025-09-24SELL-5,4127.7707.880 7.869USD -42,587 8.52 Profit of 3,541 on sale
2025-09-18BUY3647.9607.970 7.969USD 2,901 8.53
2025-09-17BUY1,0957.7007.990 7.961USD 8,717 8.53
2025-08-20SELL-1,4528.3808.390 8.389USD -12,181 8.54 Profit of 218 on sale
2025-07-30BUY1,4488.2208.390 8.373USD 12,124 8.55
2025-07-17SELL-7248.7008.720 8.718USD -6,312 8.55 Loss of -122 on sale
2025-07-11SELL-2,9048.7608.870 8.859USD -25,727 8.54 Loss of -914 on sale
2025-07-07BUY1,0898.7608.960 8.940USD 9,736 8.54
2025-07-02BUY19,9659.0209.170 9.155USD 182,780 8.53
2025-06-20BUY2,65510.10010.150 10.145USD 26,935 8.52
2025-06-11BUY70810.61011.070 11.024USD 7,805 8.43
2025-06-10BUY70811.01011.220 11.199USD 7,929 8.41
2025-06-04SELL-35411.04011.310 11.283USD -3,994 8.33 Loss of -1,047 on sale
2025-04-23BUY3547.9608.180 8.158USD 2,888 7.84
2025-04-10SELL-2,8326.4106.580 6.563USD -18,586 7.91 Profit of 3,803 on sale
2025-04-08SELL-3546.4707.080 7.019USD -2,485 7.94 Profit of 324 on sale
2025-04-07SELL-3546.7907.050 7.024USD -2,486 7.95 Profit of 327 on sale
2025-04-04SELL-1,7756.8307.180 7.145USD -12,682 7.96 Profit of 1,450 on sale
2025-04-01BUY4,4787.2507.490 7.466USD 33,433 7.98
2025-03-31SELL-1,0357.5007.710 7.689USD -7,958 7.98 Profit of 304 on sale
2025-03-21BUY5,3757.9808.100 8.088USD 43,473 7.99
2025-03-14SELL-5,2647.7007.740 7.736USD -40,722 8.01 Profit of 1,435 on sale
2025-03-07SELL-6567.6907.970 7.942USD -5,210 8.04 Profit of 65 on sale
2025-03-04SELL-3288.3108.390 8.382USD -2,749 8.04 Loss of -112 on sale
2025-02-25BUY6588.2808.440 8.424USD 5,543 8.00
2025-02-19SELL-3279.3909.480 9.471USD -3,097 7.93 Loss of -505 on sale
2025-02-13BUY9818.8208.900 8.892USD 8,723 7.83
2025-02-12BUY3278.7809.000 8.978USD 2,936 7.81
2025-02-11BUY1,3088.9909.000 8.999USD 11,771 7.79
2024-12-30SELL-13,0127.5307.710 7.692USD -100,088 7.67 Loss of -300 on sale
2024-11-18SELL-5,4457.0607.140 7.132USD -38,834 7.88 Profit of 4,095 on sale
2024-11-08SELL-3637.7807.840 7.834USD -2,844 7.90 Profit of 23 on sale
2024-10-30BUY3,4768.3708.370 8.370USD 29,094 7.99
2024-10-21SELL-3547.5207.660 7.646USD -2,707 0.00 Loss of -2,707 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BCRX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19564,07678,653998,53456.5%
2025-09-18249,0465,213665,74137.4%
2025-09-17626,53501,344,62446.6%
2025-09-16416,5420849,25049.0%
2025-09-15513,6988731,366,16837.6%
2025-09-12336,3942401,653,91320.3%
2025-09-11343,166700941,86536.4%
2025-09-10481,8735,6841,056,28545.6%
2025-09-09312,2522,013901,72534.6%
2025-09-08209,98019,598510,10241.2%
2025-09-05321,72639,7601,095,98329.4%
2025-09-04145,25516,436438,74733.1%
2025-09-03582,14562,9121,717,14533.9%
2025-09-02351,305481941,30037.3%
2025-08-29191,7674,400800,58524.0%
2025-08-28420,8010745,72556.4%
2025-08-27178,4010405,14144.0%
2025-08-26253,8500558,42045.5%
2025-08-25406,1140839,31348.4%
2025-08-22192,2620573,42133.5%
2025-08-21221,2210458,55748.2%
2025-08-20131,1660427,34430.7%
2025-08-19146,8090764,93219.2%
2025-08-18305,8800716,73042.7%
2025-08-15228,075155881,32325.9%
2025-08-14525,21301,005,23552.2%
2025-08-13329,64901,231,19226.8%
2025-08-12401,2170894,02944.9%
2025-08-11365,779100823,30444.4%
2025-08-08296,1520726,74040.8%
2025-08-07449,0730844,61753.2%
2025-08-06468,0721,801877,45253.3%
2025-08-05850,49115,7761,611,41652.8%
2025-08-042,106,7296,2703,591,01458.7%
2025-08-012,016,6955,9403,035,43666.4%
2025-07-311,474,84702,430,62260.7%
2025-07-30489,268561,010,36448.4%
2025-07-29708,7416601,471,73548.2%
2025-07-28709,7091221,144,79662.0%
2025-07-25424,2090793,87253.4%
2025-07-24482,2920791,30460.9%
2025-07-23444,1140861,55151.5%
2025-07-22599,2182001,373,17143.6%
2025-07-21427,22401,231,50334.7%
2025-07-18492,01801,083,53445.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy